M
Mehri Mollaee
Researcher at Thomas Jefferson University
Publications - 19
Citations - 1141
Mehri Mollaee is an academic researcher from Thomas Jefferson University. The author has contributed to research in topics: Cancer & Head and neck squamous-cell carcinoma. The author has an hindex of 9, co-authored 17 publications receiving 884 citations. Previous affiliations of Mehri Mollaee include Thomas Jefferson University Hospital.
Papers
More filters
Journal ArticleDOI
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Agnieszka K. Witkiewicz,Elizabeth A. McMillan,Uthra Balaji,Guem Hee Baek,Wan Chi Lin,John C. Mansour,Mehri Mollaee,Kay Uwe Wagner,Prasad Koduru,Adam C. Yopp,Michael A. Choti,Charles J. Yeo,Peter McCue,Michael A. White,Erik S. Knudsen +14 more
TL;DR: It is shown that environmental stress and alterations in DNA repair genes associate with distinct mutation spectra, and multiple novel mutated genes in PDA are identified, with select genes harbouring prognostic significance.
Journal ArticleDOI
Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial
Joseph Curry,Jennifer Johnson,Patrick Tassone,Marina Domingo Vidal,Diana Whitaker Menezes,John Sprandio,Mehri Mollaee,Paolo Cotzia,Ruth Birbe,Zhao Lin,Kurren S. Gill,Elizabeth Duddy,Tingting Zhan,Benjamin E. Leiby,Michelle L. Reyzer,David Cognetti,Adam Luginbuhl,Madalina Tuluc,Ubaldo E. Martinez-Outschoorn +18 more
TL;DR: The tumor microenvironment frequently displays abnormal cellular metabolism, which contributes to aggressive behavior, and metformin inhibits mitochondrial oxidative phosphorylation, altering metabolism.
Journal ArticleDOI
MCT1 in Invasive Ductal Carcinoma: Monocarboxylate Metabolism and Aggressive Breast Cancer.
Jennifer Johnson,Paolo Cotzia,Roberto Fratamico,Lekha Mikkilineni,Jason Chen,Daniele Colombo,Mehri Mollaee,Diana Whitaker-Menezes,Marina Domingo-Vidal,Zhao Lin,Tingting Zhan,Madalina Tuluc,Juan P. Palazzo,Ruth Birbe,Ubaldo E. Martinez-Outschoorn +14 more
TL;DR: MCT1 expression as quantified with digital image analysis may be useful as a prognostic biomarker and to design clinical trials using MCT1 inhibitors to determine its association with breast cancer subtypes and outcomes.
Journal ArticleDOI
FOXD3 Regulates VISTA Expression in Melanoma
Sheera Rosenbaum,Meghan Knecht,Mehri Mollaee,Zhijiu Zhong,Dan A. Erkes,Peter A. McCue,Inna Chervoneva,Adam C. Berger,Jennifer A. Lo,David E. Fisher,Jeffrey E. Gershenwald,Michael A. Davies,Timothy J. Purwin,Andrew E. Aplin +13 more
TL;DR: Overall, this study demonstrates melanoma cell expression of VISTA and its regulation by FOXD3, contributing to the rationale for therapeutic strategies that combine targeted inhibitors with immune checkpoint blockade.
Journal ArticleDOI
Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer
Thomas A Adams,Paris Vail,Amanda Ruiz,Mehri Mollaee,Peter A. McCue,Erik S. Knudsen,Agnieszka K. Witkiewicz +6 more
TL;DR: Interestingly, a glycolytic tumor environment, as determined by the expression of MCT4 in the tumor stroma, was associated with the immune evasive environment and poor prognosis, and four distinct triple negative breast cancer subtypes were defined that harbored prognostic significance in multivariate analysis.